PubRank

Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

Clinical Trial ID NCT00145925

PubWeight™ 140.34‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00145925

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 38.76
2 Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 21.49
3 Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 14.96
4 A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009 12.15
5 Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 10.75
6 Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 8.54
7 Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 4.43
8 Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia 2001 3.33
9 Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2011 2.28
10 Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009 1.89
11 Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009 1.68
12 Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009 1.59
13 Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation 2016 1.40
14 Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013 1.32
15 Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009 1.26
16 Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001 1.16
17 Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med 2010 1.09
18 Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014 1.07
19 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014 1.05
20 Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia 2012 0.96
21 Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011 0.96
22 Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012 0.95
23 Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc 2012 0.92
24 Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 2013 0.92
25 The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013 0.90
26 Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag 2009 0.88
27 Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 2010 0.88
28 Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens 2010 0.86
29 Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care 2015 0.83
30 Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One 2013 0.81
31 Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Ther 2015 0.79
32 Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension 2014 0.79
33 The risk of cancer in people with diabetes and chronic kidney disease. Nephrol Dial Transplant 2012 0.79
34 Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care 2014 0.78
35 Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care 2011 0.78
36 Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Ther 2015 0.78
37 Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther 2016 0.77
38 Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus. Int J Ophthalmol 2013 0.77
39 Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Ther 2016 0.76
40 Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. Med J Aust 2010 0.76
41 The effects of patient characteristics and geographical region on hospitalization in patients with type 2 diabetes. Diabet Med 2013 0.75
42 Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health 2015 0.75
43 Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia 2016 0.75
44 Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes. Diabetes Ther 2014 0.75
45 The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open 2016 0.75
Next 100